Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | GCGR | P47871 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24636898 | 1.00 | SCN9A (0.36) | SCN9ANTRK1KMT2AHIF1AEPAS1 | |
| SCHEMBL29620956 | 1.00 | SCN9A (0.36) | SCN9ANTRK1KMT2AHIF1AEPAS1 | |
| SCHEMBL22925675 | 0.89 | TRPV1 (0.40) | HIF1AEPAS1GCGR | |
| SCHEMBL22925988 | 0.89 | TRPV1 (0.40) | HIF1AEPAS1GCGR | |
| SCHEMBL29620976 | 0.89 | TRPV1 (0.40) | HIF1AEPAS1GCGR | |
| SCHEMBL29620979 | 0.89 | TRPV1 (0.40) | HIF1AEPAS1GCGR | |
| SCHEMBL22925985 | 0.89 | TRPV1 (0.40) | HIF1AEPAS1GCGR | |
| SCHEMBL22925767 | 0.87 | MAOB (0.39) | NTRK1 | |
| Hydrochloric Acid SCHEMBL29620914 | 0.86 | MAOB (0.38) | NTRK1 | |
| Hydrochloric Acid SCHEMBL28733689 | 0.86 | MAOB (0.38) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | SCN9A 4045/4885NTRK1 4716/4885KMT2A 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.